Reuters logo
BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical says HY revenue rmb272 million
August 4, 2017 / 10:51 AM / 2 months ago

BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical says HY revenue rmb272 million

Aug 4 (Reuters) - Shanghai Fudan-zhangjiang Bio-pharmaceutical Co Ltd:

* HY revenue rmb272 million versus rmb241.9 million

* HY profit attributable to shareholders of company of approximately rmb49.6 million versus about rmb45.9 million​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below